Knight Therapeutics Inc (GUD) Fair Value & Analysis
Healthcare · CA · Market cap C$845M
Fair value as of: Jun 24, 2026
From 12 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from C$16.75 to C$9.04 (−46.0%) since Jun 23, 2026. Share price +20.3% over the past month.
Price vs Fair Value (12 months)
12‑month range C$5.39 – C$9.23 · fair‑value band C$6.32 – C$11.76 · the C$9.23 price screens above the C$9.04 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Knight Therapeutics Inc (GUD) currently trades at C$9.23, while our model-based Fair Value estimate is C$9.04 — implying the stock looks roughly 2.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Knight Therapeutics Inc generated revenue of C$510M at a net margin of 1.1%. Revenue grew 68.5% year over year. It earns a return on equity of 0.7%. Net debt stands at C$1.5M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvex…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Knight Therapeutics Inc reported revenue of C$450M in FY2025 versus C$243M in FY2021, a compound +16.6%/yr. Reported net income was −C$5.4M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Knight Therapeutics Inc (GUD) undervalued?
What is the fair value of GUD?
What is the quality score of GUD?
What is the revenue of Knight Therapeutics Inc (GUD)?
What is the net profit margin of GUD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.